@article{a8b333df519c4604bc58567cf46c4012,
title = "PCSK9 is a promising prognostic marker in patients with advanced NSCLC",
keywords = "afatinib, carboplatin, cisplatin, erlotinib, gefitinib, gemcitabine, nivolumab, osimertinib, programmed death 1 ligand 1, proprotein convertase 9, selumetinib, vinorelbine tartrate, antineoplastic agent, PCSK9 protein, human, tumor marker, advanced cancer, cancer patient, cancer prognosis, human, Letter, non small cell lung cancer, priority journal, treatment outcome, cancer staging, lung tumor, metabolism, mortality, prognosis, survival analysis, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging, Nivolumab, Prognosis, Proprotein Convertase 9, Survival Analysis",
author = "A. Bonaventura and F. Grossi and F. Montecucco",
note = "Export Date: 19 May 2020 CODEN: CIIMD Correspondence Address: Bonaventura, A.; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, Italy; email: aldo.bonaventura@vcuhealth.org",
year = "2020",
doi = "10.1007/s00262-020-02485-z",
language = "English",
volume = "69",
pages = "491--492",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",
}